Post-Traumatic Stress Disorder (PTSD) Therapeutics

Post-Traumatic Stress Disorder (PTSD) Therapeutics

Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market to Reach US$4.0 Billion by 2030

The global market for Post-Traumatic Stress Disorder (PTSD) Therapeutics estimated at US$2.9 Billion in the year 2023, is expected to reach US$4.0 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Anxiolytics segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$791.2 Million While China is Forecast to Grow at 4.2% CAGR

The Post-Traumatic Stress Disorder (PTSD) Therapeutics market in the U.S. is estimated at US$791.2 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$625.8 Million by the year 2030 trailing a CAGR of 4.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market - Key Trends and Drivers Summarized

Post-Traumatic Stress Disorder (PTSD) Therapeutics: Advancements in Mental Health Care

Post-Traumatic Stress Disorder (PTSD) is a debilitating mental health condition that can develop after an individual experiences or witnesses a traumatic event, such as warfare, natural disasters, or violent assaults. Symptoms of PTSD include intrusive thoughts, nightmares, severe anxiety, and emotional numbness, which can significantly impair daily functioning and quality of life. Treatment for PTSD typically involves a combination of psychotherapy and pharmacotherapy. Cognitive Behavioral Therapy (CBT), specifically trauma-focused CBT, is one of the most effective psychotherapeutic approaches, helping patients process traumatic memories and reduce distressing symptoms. Pharmacotherapy often includes selective serotonin reuptake inhibitors (SSRIs) and other antidepressants, which can help alleviate mood and anxiety symptoms associated with PTSD. The comprehensive approach to treating PTSD aims to address both the psychological and physiological aspects of the disorder.

How Are Technological Advancements Enhancing PTSD Therapeutics?

Technological advancements are playing a critical role in enhancing PTSD therapeutics, providing new avenues for treatment and management. Innovations in digital health, such as telemedicine and mobile health applications, have increased access to mental health services, allowing patients to receive therapy remotely. Virtual reality (VR) therapy is an emerging treatment modality that uses immersive VR environments to safely expose patients to traumatic memories in a controlled setting, facilitating therapeutic processing. Advances in neuroimaging techniques, such as functional MRI (fMRI) and PET scans, are improving our understanding of the neural mechanisms underlying PTSD, guiding the development of targeted treatments. Additionally, breakthroughs in pharmacogenomics are paving the way for personalized medicine, enabling the customization of pharmacotherapy based on an individual`s genetic profile. These technological innovations are enhancing the effectiveness and accessibility of PTSD therapeutics, offering new hope for patients.

What Are the Key Therapeutic Approaches and Benefits for PTSD?

The therapeutic approaches for PTSD encompass a range of psychotherapies and pharmacotherapies, each offering distinct benefits. Trauma-focused Cognitive Behavioral Therapy (CBT) and Eye Movement Desensitization and Reprocessing (EMDR) are widely recognized as effective psychotherapeutic interventions, helping patients process traumatic memories and reduce symptoms. Pharmacotherapy, including anxiolytics, SSRIs and other antidepressants, is beneficial for managing co-occurring symptoms such as depression and anxiety. Additionally, emerging treatments like ketamine infusion therapy and MDMA-assisted psychotherapy are showing promise in clinical trials, offering rapid symptom relief and long-lasting effects. The comprehensive treatment of PTSD also includes complementary therapies such as mindfulness meditation, yoga, and art therapy, which can enhance emotional regulation and overall well-being. The primary benefits of these therapeutic approaches are symptom reduction, improved daily functioning, and enhanced quality of life for individuals with PTSD.

What Factors Are Driving the Growth in the PTSD Therapeutics Market?

The growth in the post-traumatic stress disorder (PTSD) therapeutics market is driven by several factors. The increasing prevalence of PTSD, particularly among military personnel, first responders, and survivors of violence and disasters, is a significant driver. Technological advancements that enhance treatment accessibility and efficacy, such as telemedicine, virtual reality therapy, and personalized medicine, are also propelling market growth. The rising awareness and destigmatization of mental health issues are encouraging more individuals to seek treatment, boosting demand for PTSD therapeutics. Additionally, ongoing research and development efforts are leading to the discovery of novel therapeutic agents and treatment modalities, expanding the range of available options. The growing investment in mental health infrastructure and services, particularly in developing regions, is further contributing to market growth. These factors, coupled with the increasing recognition of PTSD as a critical public health issue, are driving the sustained growth of the PTSD therapeutics market.

Select Competitors (Total 31 Featured) -
  • Apotex, Inc.
  • AstraZeneca PLC
  • Azevan Pharmaceuticals, Inc.
  • Bionomics Ltd.
  • GlaxoSmithKline PLC
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Tonix Pharmaceuticals Holding Corporation
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Post-Traumatic Stress Disorder (PTSD) Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Prevalence of PTSD and Mental Health Disorders Propels Market Growth
Rising Awareness and Diagnosis of PTSD Drives Market Expansion
Technological Innovations in Therapeutics Strengthen Business Case
Development of Novel Drug Therapies Generates New Opportunities
Advancements in Psychotherapy and Counseling Propel Market Growth
Growing Use of Telemedicine and Digital Health Solutions Drives Adoption
Expansion of Applications in Military and Veteran Care Throws Spotlight on Market Potential
Development of Biomarkers for PTSD Generates New Opportunities
Growing Focus on Combination Therapies Spurs Market Expansion
Growth in Mental Health Awareness Campaigns Expands Market Horizons
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Anxiolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Anxiolytics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Anxiolytics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 13: World Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 14: USA Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 15: USA Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: USA 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
CANADA
TABLE 17: Canada Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: Canada Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: Canada 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
JAPAN
Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 20: Japan Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: Japan Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: Japan 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
CHINA
Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 23: China Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: China Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: China 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
EUROPE
Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 26: Europe Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: Europe Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Europe 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 29: Europe Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Europe Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Europe 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
FRANCE
Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 32: France Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: France Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: France 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
GERMANY
Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 35: Germany Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Germany Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Germany 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
ITALY
TABLE 38: Italy Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Italy Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Italy 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
UNITED KINGDOM
Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 41: UK Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: UK Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: UK 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Rest of Europe Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Rest of Europe 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Asia-Pacific Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Asia-Pacific 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 50: Rest of World Recent Past, Current & Future Analysis for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Rest of World Historic Review for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Antidepressants, Anxiolytics and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Rest of World 16-Year Perspective for Post-Traumatic Stress Disorder (PTSD) Therapeutics by Product - Percentage Breakdown of Value Sales for Antidepressants, Anxiolytics and Other Products for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings